- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02845050
Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO) (JaNEO)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Baldingerstraße
-
Marburg/ Lahn, Baldingerstraße, Germany, 35033
- Dept. Urology, University Hospital Marburg
-
-
Hoppe-Seyler-Straße 3
-
Tübingen, Hoppe-Seyler-Straße 3, Germany, 72076
- Dept. Urology, University Hospital Tübingen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients aged ≥ 18 years and ≤ 75 years with legal capacity
- Signed written informed consent
- Histologically confirmed muscle-invasive urothelial cell carcinoma of the bladder (MIBC) with clinical T2-T4a (N0/Nx, M0) assessed by primary PDD-guided TUR-B and by the screening imaging (MRI pelvis and CT chest/abdomen) which both must include the use of contrast medium
- Confirmed adequate complete resection of all visible tumor during TUR-B according to current treatment guidelines before registration; the latest TUR-B must have been done ≤ 8 weeks before registration
- ECOG performance status of 0 or 1
Adequate bone marrow, renal and hepatic functions as evidenced by the following:
- Absolute Neutrophil Count ≥ 2,000 mm3 and ≤ 7,500 mm3
- Hemoglobin ≥ 12 g/dL for the safety phase of the study; if the study treatment proved to be adequate tolerated during this safety phase, the threshold can be lowered to ≥ 10 g/dL according to the decision of the study steering committee
- Platelet count ≥ 100,000 mm3
- Serum albumin within normal range
- Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- Transaminases (ALT, AST) ≤ 1.5 x ULN
- Creatinine clearance ≥ 60 mL/min, calculated based on a 24h-measured creatinine clearance
- Serum Urea < 25 mg/100 ml
- Absence of psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; these conditions should be assessed with the patient before registration
- Electrocardiogram (ECG) without modifications that suggest a high risk of occurrence of an acute clinical event (such as signs of angina pectoris or high-risk arrhythmia, etc.); cardiologist consultation is required, if relevant abnormalities are observed in the screening ECG-assessment
Exclusion Criteria:
- Prior systemic chemotherapy for any kind of malignancy; prior intravesical chemotherapy or treatment with BCG is allowed
- Prior radiation of the pelvis or any prior radiation to ≥ 30 % of the bone marrow
- Evidence of lymph node (N+) or distant metastasis (M1) in the screening imaging assessment, including known brain metastases or leptomeningeal involvement (however, brain-MRI-scans are not required to rule out CNS-involvement, unless there is clinical suspicion of central nervous system (CNS) disease)
- Any contraindication with regard to contrasted imaging (MRI or CT)
- Other malignancies except adequately treated basal carcinoma of the skin, localized prostate cancer Gleason ≤ 6, in-situ cervix carcinoma or any other tumor with a disease free interval ≥ 5 years
- Peripheral neuropathy Grade ≥ 2 NCI CTCAE v4.03 or hearing impairment Grade ≥ 2 NCI CTCAE v.4.03
- Any concurrent chronic system immune therapy or previous organ allograft
- Weight loss > 5 % within the last 3 months before registration
Any other serious illness or medical condition including:
- Infection requiring systemic anti-infective therapy within the last 2 weeks before registration
- History of cardio-vascular disease that might compromise the safe administration of cisplatin
- Dehydration requiring IV fluid substitution
- Any medical condition that might not be controlled, e.g. patients with unstable angina pectoris, myocardial infarction < 6 months before registration or uncontrolled diabetes, congestive cardiac failure > NYHA grade I
- Known hypersensitivity to the study drugs or to drugs with similar chemical structures
- Treatment with any potent CYP3A4 inhibitor or inductor (e.g. ketoconazole, itraconazole, ritonavir, amprenavir, indinavir, rifampicine) or phenytoine; replacement of such treatment with alternative treatment options before start of study treatment is acceptable, if medically feasible and ethically acceptable
- 12. Treatment with any medication that is known to prolong the QT/QTc interval and/or to cause Torsades de Pointes (e.g. azithromycine, amitryptiline, imipramine, clozapine, flu-ox¬etine, cisapride); replacement of such treatment with alter¬na¬ti¬ve options before start of study treatment is acceptable, if medically feasible and ethically acceptable
- Treatment with hexamethylmelamin, pyridoxine, penicillamine or any other drug with known potential to affect the efficacy of cisplatin
- Treatment with any other investigational or anti-cancer therapy ≤ 30 days before registration
- Pregnant or lactating female patients or female patients of childbearing potential with positive pregnancy test at screening
- Women of child-bearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 6 months after the study
- Sexually active fertile men, who are unwilling or unable to use an effective birth control from day of informed consent and for up to 6 months after the last cycle of chemotherapy, if their partners are women of child-bearing potential (if cystectomy is not performed) effective birth control means the use of condoms ideally combined with any acceptable contraception of the male patient's partner as described in exclusion criterion 16
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Vinflunine+Cisplatin+radical cystectomy
neoadjuvant combination of Vinflunine+Cisplatin before radical cystectomy as proof of principle (one arm only!)
|
One cycle is defined as a period of 3 weeks of treatment: Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion Cisplatin (70 mg/m²) on Day 2, every 21 days 4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy One cycle is defined as a period of 3 weeks of treatment: Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion Cisplatin (70 mg/m²) on Day 2, every 21 days 4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy
max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathological Complete Response (pCR)
Time Frame: cystectomy
|
Rate of pathological complete response (pCR) at cystectomy assessed by central pathological review (Prof.
Hartmann, Erlangen), if the initial safety phase allows continuation of the trial with the phase II part
|
cystectomy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall radiological response rate before cystectomy
Time Frame: prior cystectomy
|
RECIST v1.1
|
prior cystectomy
|
Progression rate
Time Frame: after 2 and 4 cycles (of 21 days length) of treatment
|
RECIST v1.1
|
after 2 and 4 cycles (of 21 days length) of treatment
|
Safety of chemotherapy measured by adverse events and clavien-dindo grades
Time Frame: through study completion after 12 months-follow up
|
An evaluation of adverse events and serious adverse events will be done.
Alle analyses of adverse events will be done using the CTCAE-classification v4.03.
Events of grade 3-4 will be evaluated seperatly.
Also, all events reported to be related to cystectomy will be evaluated using the clavien-dindo-grades.
|
through study completion after 12 months-follow up
|
Rate of complications at cystectomy
Time Frame: at cystectomy
|
at cystectomy
|
|
Perioperative morbidity/mortality
Time Frame: 30 days and 90 days post surgery
|
30 days and 90 days post surgery
|
|
Cancer-specific survival
Time Frame: one year after cystectomy
|
Evaluation will be done from date of study registration to death on disease or the last visit date (if not death at timepoint of evaluation).
Patients that died due to other reasons than cancer will be evaluated with their last date known alive.
|
one year after cystectomy
|
QoL - GIQLI
Time Frame: Cycle 1-4 Day 1+ cystectomy + 1,3 and 12 months after cystectomy
|
If Values for total or subscale scores are missing, no imputation will be applied.
To summarize scored scales descriptive statistics will be used.
Patients with an evaluable baseline score and at least one evaluable post baseline score will be included into analyses to evaluate changes from baseline.
|
Cycle 1-4 Day 1+ cystectomy + 1,3 and 12 months after cystectomy
|
QoL - QLQ-C30
Time Frame: Cycle 1-4 Day 1+ cystectomy + 1,3 and 12 months after cystectomy
|
If Values for total or subscale scores are missing, no imputation will be applied.
To summarize scored scales descriptive statistics will be used.
Patients with an evaluable baseline score and at least one evaluable post baseline score will be included into analyses to evaluate changes from baseline.
|
Cycle 1-4 Day 1+ cystectomy + 1,3 and 12 months after cystectomy
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse rate and location of relapse not RECIST-standardized
Time Frame: at 1 month, 3 months and 1 year after cystectomy
|
Evaluated will be the number of patients with relapse 1, 3 and 12 months after cystectomy.
The same evaluation will be done seperately for different locations of relapse, e. g. local relapse, distant metastases (lung, liver, bone, extraregional lymp nodes)
|
at 1 month, 3 months and 1 year after cystectomy
|
Biobanking
Time Frame: Day 1 of cyle 1-4, Day 15 of cyle 1, at cystectomy, 1, 3 and 12 months follow up, and baseline for tumour tissue
|
Blood, urine and tissue will be collected in a biobank for further evaluations that are not determined yet.
|
Day 1 of cyle 1-4, Day 15 of cyle 1, at cystectomy, 1, 3 and 12 months follow up, and baseline for tumour tissue
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- JaNEO-001
- 2016-000081-33 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
Clinical Trials on Vinflunine
-
Veeda OncologyBristol-Myers SquibbCompletedNon-Small Cell Lung CancerUnited States
-
SCRI Development Innovations, LLCBristol-Myers SquibbCompletedLung Cancer | Carcinoma, Small CellUnited States
-
Institute of Cancer Research, United KingdomSt George's Healthcare NHS TrustCompletedLocally-advanced or Metastatic Penile NeoplasmsUnited Kingdom
-
Associació per a la Recerca Oncologica, SpainUnknownUrothelium Transitional Cell CarcinomaSpain, Netherlands
-
Bristol-Myers SquibbTerminatedStomach CancerKorea, Republic of, Philippines, Malaysia
-
SCRI Development Innovations, LLCBristol-Myers SquibbCompleted
-
Bristol-Myers SquibbPierre Fabre MedicamentCompletedKidney Neoplasms | Transitional Cell Carcinoma | Bladder Cancer | Bladder Neoplasms | Ureter Neoplasms | Neoplasm, BladderUnited States, Spain, Italy, Canada, Indonesia, Singapore, Australia, Austria, France, Greece, Korea, Republic of, Philippines, Sweden, Switzerland, Thailand
-
Bristol-Myers SquibbCompleted
-
Pierre Fabre MedicamentBristol-Myers SquibbCompletedBladder Cancer | Bladder Neoplasms | Transitional Cell Carcinoma of the Urothelial TractCanada
-
Spanish Oncology Genito-Urinary GroupCompletedCarcinoma, Transitional CellSpain